Phase 4 N=23 Bepreve vs. Alrex in Subjects With Moderate to Severe Allergic Conjunctivitis
Allergic Conjunctivitis
Primary: Change From Baseline in Ocular Itching at 14 Days — 2.17; 1.82 units on a scale
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 3 N=169 Double-Masked Trial of NOVA22007 (1mg/mL Ciclosporin/Cyclosporine) Versus Vehicle in Pediatric Patients With Active Severe Vernal Keratoconjunctivitis
Vernal Keratoconjunctivitis
Primary: Average Penalties Adjusted Composite Efficacy Score (CFS) Score Over the 4 Months — 2.06; 1.93; 1.34 Penalties Adjusted CFS Score — p=0.007
Phase 3 N=118 Efficacy and Tolerance of Nova22007 Versus Vehicle in Patients With Vernal Keratoconjunctivitis (VKC)
Conjunctivitis, Vernal
Primary: Overall Rating of Subjective Symptoms of VKC in Period I — 7; 1; 4; 5 Participants — p=0.2699
Phase 3 N=140 AGN-229666 Ophthalmic Solution for the Treatment of Seasonal or Perennial Allergic Conjunctivitis
Conjunctivitis, Allergic
Primary: Change From Baseline In Ocular Itching Frequency Score Using a 6-point Scale — 4.4; -3.4 Scores on a Scale
Phase 3 N=130 A Long-term Study of DE-114 Ophthalmic Solution in Patients With Allergic Conjunctivitis
Allergic Conjunctivitis
Primary: Change in Ocular Itching Score by Visit — -0.6; -0.9; -1.3; -1.7 score
Phase 2 N=90 AGN-229666 for the Treatment of Allergic Conjunctivitis
Allergic Conjunctivitis
Primary: Ocular Itching Score at Day 1 — 0.500; 0.319; 1.867 Score on a scale
N/A N=21 Effect of Olopatadine on Allergic Tear Mediators
Allergic Conjunctivitis
Primary: Study Examined Whether the Incubation of Human Conjunctival Epithelial Cells With Tears Pooled From Allergic Subjects (One Eye With and Other Eye Without Olopatadine…
Phase 2 N=120 Study Evaluating the Efficacy and Safety of PRT-2761 for the Treatment of Acute and Chronic Allergic Conjunctivitis
Allergic Conjunctivitis
Primary: Ocular Itching at 5, 7, and 10 Minutes Post CAC on Day 1 — 2.573; 2.500; 1.217; 2.647 units on a scale
Phase 4 N=18 Non-Pharmaceutical Treatment of Seasonal Allergic Conjunctivitis
Hypersensitivity
Primary: Symptoms — 15.3; 11.3; 13.3; 9.8 Units on a scale
Phase 3 N=345 Efficacy and Safety of an Ophthalmic Solution in Patients With Allergic Conjunctivitis
Allergic Conjunctivitis
Primary: Mean Ocular Itching at Onset of Action — 0.38; 0.47; 0.59; 1.91 units on a scale
Phase 4 N=20 Study of the Effect of Fluticasone Furoate Nasal Spray on Spring Allergy Eye Symptoms
Allergic Conjunctivitis to Tree Pollen or Grass Pollen
Primary: Eosinophilic Cationic Protein (ECP) Levels
Phase 2 N=47 Safety and Efficacy of VSJ-110 in the Treatment of Allergic Conjunctivitis in Adults With a History of Ocular Allergies
Allergic Conjunctivitis
Primary: Ocular Itching as Measured by Self-reported Numerical Scales — -0.228; 0.010; -0.424; -0.035 score on a scale
Phase 4 N=16 Evaluation of Prednisolone in a Modified Conjunctival Allergen Challenge Model
Chronic Allergic Conjunctivitis
Primary: Inflammation Change From Baseline to Day 6 — -1.2; -0.19 score on a scale
Phase 3 N=130 Efficacy and Safety Study of Bepotastine Besilate Ophthalmic Solution in Allergic Conjunctivitis
Allergic Conjunctivitis
Primary: Ocular Itching — 0.4; 1.9; 0.4; 0.5 Units on a scale
Phase 4 N=13 Confocal Analysis of Corneal Structures of Symptomatic Allergic Conjunctivitis Patients
Allergic Conjunctivitis
Primary: Patient-Assessed Ocular Itching — 2.2; 2.2; 0.5; 0.5 units on a scale
Phase 3 N=73 OTX-14-007: A Phase 3 Study Evaluating the Safety and Efficacy of OTX-DP for the Treatment of Chronic Allergic Conjunctivitis
Chronic Allergic Conjunctivitis
Primary: Ocular Itching Post-CAC (Conjunctival Allergen Challenge) at Visit 6 — 1.68; 2.66 units on a scale
Phase 3 N=240 AGN-229666 Ophthalmic Solution in Japanese Patients With Allergic Conjunctivitis
Conjunctivitis, Allergic
Primary: Ocular Itching Score — 0.33; 1.48; 0.29 score on a scale
Phase 2 N=68 OTX-14-001: A Phase 2 Study Evaluating the Safety and Efficacy of OTX-DP for the Treatment of Chronic Allergic Conjunctivitis
Chronic Allergic Conjunctivitis
Primary: Ocular Itching — 1.80; 2.58; 1.72; 2.70 units on a scale (0 -4)
Phase 2 N=154 A Study of ADX-102 in Subjects With Allergic Conjunctivitis
Conjunctivitis, Allergic
Primary: Ocular Itching Evaluated by the Subject at 10(±1) Minutes Post the Ora Calibra® Conjunctival Allergen Challenge at Day 15. — 2.020; 2.398; 2.515 units on a scale
Phase 3 N=300 Alrex® Versus Patanol in the Treatment of Seasonal Allergic Conjunctivitis(SAC)
Seasonal Allergic Conjunctivitis
Primary: Bulbar Conjunctival Injection — -1.91; -1.71 units on a scale
Phase 3 N=87 Study of DE-114 Ophthalmic Solution in Patients With Allergic Conjunctivitis
Allergic Conjunctivitis
Primary: Mean Ocular Itching Score Compared to Placebo Period1 — 0.4; 1.7 score — p=<0.001
Phase 2 N=245 Safety and Efficacy of Bepotastine Besilate Ophthalmic Solution in Seasonal Allergic Conjunctivitis Patients
Allergic Conjunctivitis
Primary: Rhinoconjunctivitis Quality of Life Questionnaire (RQLQ) - Mean Change in Total Score — -1.18; -1.17 score on a scale
Phase 3 N=229 Evaluation of Brimonidine Tartrate/Ketotifen Fumarate Combination in Adults With Seasonal Allergic Conjunctivitis
Seasonal Allergic Conjunctivitis
Primary: Ocular Itching Symptom Score — 0.175; 0.085; 0.267; 0.098 score on a scale
Phase 2 N=121 A Single-Center, Phase 2 Study Evaluating Bilastine Ophthalmic Solution in the CAC® Model
Allergic Conjunctivitis
Primary: Ocular Itching — 1.908; 1.925; 1.177; 2.758 units on a scale — p=0.0002
Phase 3 N=101 Efficacy of AC-170 for the Treatment of Allergic Conjunctivitis in the Conjunctival Allergen Challenge (CAC) Model
Allergic Conjunctivitis
Primary: Ocular Itching at Duration of Action (16 Hours Post-dose) — 1.91; 2.00; 1.65; 2.48 units on a scale
Phase 2 N=100 A Safety and Activity Study of NS2 in Subjects With Allergic Conjunctivitis
Allergic Conjunctivitis · Seasonal Allergies
Primary: Ocular Itching Score at Day 14, 60 Minutes Into the Allergen Challenge — -1.550; -1.013 units on a scale
Phase 2 N=101 Loteprednol Ophthalmic Base Compared to Loteprednol Ophthalmic Suspension vs Placebo in an Allergen Challenge
Allergic Conjunctivitis
Primary: Ocular Itching — 1.48; 1.84; 1.82; 1.93 Units on a Scale
Phase 4 N=50 Effectiveness of Olopatadine HCl Ophthalmic Solution for the Treatment of Allergic Conjunctivitis in Japan
Allergic Conjunctivitis
Primary: Mean Ocular Itching at 7 Minutes Post-CAC, Day 1 — 0.23; 0.37 units on a scale
Phase 2 N=52 A Methodology Development Environmental Clinical Trial of Reproxalap in Subjects With Seasonal Allergic Conjunctivitis
Allergic Conjunctivitis
Primary: Change From Baseline Ocular Itching Score on High Pollen Days — -0.65; 0.16; -0.69 units on a scale
Phase 4 N=36 Evaluation of the Efficacy of Topical Ophthalmic Steroids in a Modified Conjunctival Allergen Challenge (CAC) Model
Allergic Conjunctivitis
Primary: Ocular Itching at Baseline (Day 0) — 2.53; 3.08; 2.61; 2.5 units on a scale